„The time has come for the old dinosaurs to go“
I read about PCSK9-inhibitors Alirocumab (Sanofi) and Evolocumab (Amgen). PCSK9-inhibitors are used in the therapy of increased cholesterol levels. It is claimed, with PCSK9 lp(a) should also fall by 20 - 30 percent. On the other hand, clinical trials (Cardiology HDZ NRW/Germany, Clin Res Cardiol 106, Suppl 2 Oct 2017) have shown that there has been no statistically significant reduction in lp(a).
They take the dusty cholesterol hypothesis of „old“ Ancel Keys from the historical medical museum as the cause of heart disease. But they are fighting a hopeless battle. Have cholesterol-lowering drugs success? No! They haven‘t. Cardiovascular diseases are still the killer number one. It remains the case that the cause of heart disease is not cholesterol or lp(a), but a lack of vital substances in the body, especially vitamin C. This is the only way to fight the disease according to Pauling/Rath (I‘m sure they are right. As said in my book „Jimmy Blue“). But BigPharma don‘t want that.
Paul Taylor wrote about another PCSK9-inhibitor (Bococizumab): „Pfizer announced on Nov 2016 it was scrapping its cholesterol drug Bococizumab. The product was not likely to provide value to patients, physicians and shareholders.“ I understood. The „story“ of PCSK9-inhibitors and other drugs. (
https://www.dr-rath-foundation.org/2016 ... has-burst/)